Invisible orthodontics provider Impress secures $125 million in Series B

Impress Founders - Dr Khaled Kasem (L), Diliara and Vladimir Lupenko

Impress, the European invisible orthodontics provider, recently announced a $125 million (£105m) Series B funding round.

The company was founded in 2019 in Barcelona by renowned orthodontist Dr. Khaled Kasem and serial entrepreneurs Diliara and Vladimir Lupenko, with the idea of combining the best of orthodontic tradition with the most innovative technology in the sector.

In just three years Impress already has more than 130 clinics across eight different countries, including all strategic markets: Spain, Italy, Germany, France, and the UK, creating a unique and scalable business model with a strong base of proven success. Impress HQ is in Barcelona, and it has a global team of 1,000 employees, of which 500 of its team are medical professionals specialised in orthodontics.

Recently Impress also put into operation one of the largest European R&D and clear aligner production facility. Even though the company was founded just three years ago, 80% of its clinics are already profitable and show very strong growth.

“We created a new orthodontic experience powered by tech. All the processes are fully digitalised thanks to Impress’ own product and software. This accomplishment would not have been possible without close contact between our patients and medical team because this is the only way we can understand their needs and expectations”, says Diliara Lupenko, Co-founder and COO of Impress.

The fresh financing will be used for further expansion in Europe (organic and M&A), further investment in tech and extending of the in-house production facility. “We are building the global leader in next-generation orthodontics”, emphasises Lupenko.

Peter Stein, Executive Chairman at Norgine Ventures, said: “We are very excited by our investment in Impress. The clear aligner market represents an attractive growth opportunity. With this investment, we support a company that, since its inception in 2019, has achieved significant growth and geographical expansion, with a differentiated offering focusing on quality of care, patient journey and operational efficiency, and is well-positioned to further grow and capture a significant share of the market.”